Drug intelligence / Profile preview

OSTEOGROW-B

Development stage: Unknown
Lead developer: Genera Research
Modality: Recombinant Proteins and Enzymes
Administration: Implant

Overview

**OSTEOGROW-B** is a Genera Research investigational bone-regeneration implant for transforaminal lumbar interbody fusion. It comprises recombinant human bone morphogenetic protein 6 delivered in an autologous blood coagulum and enriched with host bone harvested from the patient's spine. BMP6 provides an osteoinductive signal intended to promote new bone formation and accelerate vertebral fusion. Genera Research reports that OSTEOGROW-B was evaluated in a completed multicentre, double-blinded randomized Phase I/II trial in 60 patients undergoing transforaminal lumbar interbody fusion.

Targets

BMPR1BBMPR1ABMPR2 (Bone morphogenetic protein receptor type II)ACVR2A/B (Activin receptor type-2A (ACVR2A) and Activin receptor type-2B (ACVR2B))

Beyond the preview

Go deeper on OSTEOGROW-B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSTEOGROW-B.

Explore the full profile